Clinical Trial Update: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating tafasitamab plus lenalidomide in mantle cell lymphoma has been terminated, and results were posted on 2025-04-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mantle Cell Lymphoma, MCL | Phase 2 | Status: TERMINATED | Results posted: 2025-04-20